You are here: Industry Insights > Depressive

News List

Depressive Symptoms Increased Among Seniors During COVID-19 drugs
December 28, 2021
During the COVID-19 pandemic, there was an increase in the prevalence of clinically significant depressive symptoms among older adults, according to a study published online Dec. 22 in JAMA Psychiatry.
EAN Congress: COVID-19 leads to significant cognitive and behavioural problems in patients prnasia
June 21, 2021
COVID-19 patients suffer from cognitive and behavioural problems two months after being discharged from hospital, a new study presented at the 7th Congress of the European Academy of Neurology has found[1].
Alembic Pharma gets USFDA Final nod for Lurasidone Hydrochloride Tablets expresspharma
May 17, 2021
They are indicated for monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression).
Campbell Neurosciences Files Patent on QuadraMune for Major Depressive Disorder americanpharmaceuticalreview
December 10, 2020
Therapeutics Solution International announced new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
Janssen Announces Approval of SPRAVATO for Major Depressive Disorder with Acute Suicidal Ideation americanpharmaceuticalreview
August 10, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant.
US FDA approves SPRAVATO, antidepressant medication from J&J expresspharma
August 05, 2020
The drug indicated to treat adults with major depressive disorder and acute suicidal ideation or behaviour reportedly begins improving depressive symptoms with the first dose.
OWP Announces Patent Application for Duloxetine Hydrochloride Powder for Depression, Anxiety americanpharmaceuticalreview
July 20, 2020
OWP Pharmaceuticals has submitted for U.S. patent protection for the first powder for oral liquid formulation of duloxetine hydrochloride.
fMRI Measures May Predict Psychiatric Symptoms in Children drugs
January 02, 2020
Resting-state functional magnetic resonance imaging (fMRI) measures may be able to predict symptoms of attention-deficit/hyperactivity disorder or major depressive disorder in children ...
Sertraline Does Not Reduce Depressive Symptoms by Week 6 drugs
September 23, 2019
For patients with depression, sertraline does not reduce depressive symptoms at six weeks, but it does improve anxiety, mental health-related quality-of-life, and self-reported mental health ...
New Data from SPRAVATO™ Studies Showed Rapid Reduction of Depressive Symptoms americanpharmaceuticalreview
September 10, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive results from two pivotal Phase 3 clinical studies (ASPIRE I & II) to evaluate the efficacy...

Previous page 1 2 Next page